Point-of-care Intestinal Ultrasound in IBD Patients: Disease Management and Diagnostic Yield in a Real-world Cohort and Proposal of a Point-of-care Algorithm.

"Conflict of Interest SB has served as speaker for Abbvie, Merck, Sharp & Dome, Takeda, Jansen Cilag, Pfizer, and Tillotts. FV received speaker fees or honoraria from AbbVie and Janssen. MJ received speaker fees from Biogen. VML has served as speaker and/or principal investigator for Abbvie, Covidien, Dr. Falk, Ferring Pharmaceuticals, Merck Sharp & Dohme, Receptos, Takeda, Tillotts; and Tramedico; he has received research grants from AbbVie, Merck Sharp & Dohme, Achmea Healthcare and ZonMW. MD received advisory fees from Echo Pharma and Robarts Clinical Trials Inc., speaker fees from Janssen, Merck, Pfizer, Takeda, and Tillotts Pharma, and non-financial support from Dr Falk Pharma. CP has received a research grant from Takeda, served as advisor for Takeda, Pliant, and Shire, and received speaker fees from Tillotts and Pfizer. GD has served as adviser for Abbvie, Ablynx, Amakem, AM Pharma, Avaxia, Biogen, Bristol Meiers Squibb, Boerhinger Ingelheim, Celgene, Celltrion, Cosmo, Covidien, Ferring, Dr. Falk Pharma, Engene, Galapagos, Gilead, Glaxo Smith Kline, Hospira, Immunic, Johnson and Johnson, Lycera, Medimetrics, Millenium/Takeda, Mitsubishi Pharma, Merck Sharp Dome, Mundipharma, Novonordisk, Pfizer, Prometheus Laboratories/Nestle, Protagonist, Receptos, Robarts Clinical Trials Inc., Salix, Sandoz, Setpoint, Shire, Teva, Tigenix, Tillotts, Topivert, Versant, and Vifor, and received speaker fees from Abbvie, Ferring, Johnson and Johnson, Merck Sharp Dome, Mundipharma, Norgine, Pfizer, Shire, Millenium/Takeda, Tillotts, and Vifor. KG has received grants from Pfizer and Celltrion, consultancy fees from AbbVie, Arena Pharmaceuticals, ​Galapagos, Gilead, Immunic Therapeutics, Janssen Pharmaceuticals, Novartis, Pfizer, Samsung Bioepis, and Takeda, and speaker’s honoraria from Celltrion, Ferring, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, Takeda, and Tillotts."

"Funding Dr. Falk Pharma Benelux B.V. financially supported implementation of IUS at our clinic."